---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-002705"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-05-14T20:11:39+00:00"
generated_at: "2026-05-14T20:54:38.020359+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Silexion reports positive preclinical SIL204 data showing increased MHC-I in KRAS-mutated pancreatic cancer

## Summary
- SIL204 significantly increased MHC-I (HLA-ABC) surface expression in human KRAS G12R pancreatic cancer cells at 60 nM (p<0.05).
- Increased MHC-I may enhance T cell recognition, supporting potential combination with anti-PD-1 therapies like Keytruda.
- CEO Ilan Hadar said SIL204 may influence immune evasion pathways in addition to direct anti-tumor activity.
- Pancreatic cancer is immunologically resistant; MHC-I loss is a key immune evasion mechanism in KRAS-driven tumors.

## SEC filing metadata
- accession: 0001178913-26-002705
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-05-14T20:11:39+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326002705/0001178913-26-002705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326002705/zk2635307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-002705
- JSON: https://secwatch.observer/filing/0001178913-26-002705.json
- Plain text: https://secwatch.observer/filing/0001178913-26-002705.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.